- iRhythm Technologies ( NASDAQ: IRTC ) said on Friday it had received U.S. Food and Drug Administration clearance for its ECG Utilization Software ZEUS System for the Zio Watch.
- The ZEUS System combines algorithms with cardiac arrhythmia service.
- iRhythm plans to launch the ZEUS System for a limited market evaluation in 2023.
- "iRhythm is focused on redefining the standard of care with earlier insight to predict and prevent disease, and the Zio Watch with ZEUS System provides clinicians a platform that has the potential to meaningfully improve patients’ lives," said Quentin Blackford, CEO of iRhythm.
For further details see:
iRhythm gains FDA clearance for ECG software ZEUS system